@article{c245e58a7fb6409cadc97012e22ef5af,
title = "Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study",
author = "Ida Schregel and Ramos, \{Guilherme P.\} and Stephanie Ioannou and Emma Culver and Martti F{\"a}rkkil{\"a} and Christoph Schramm and \{International PSC Study Group\} and John Eaton and Cynthia Levy and Olivier Chazouilleres and Tobias M{\"u}ller and Jeremy Nayagam and Deepak Joshi and Ehud Zigmond and Oren Shibolet and Drenth, \{Joost P. H.\} and Frank Hoentjen and Anja Geerts and Weism{\"u}ller, \{Tobias J.\} and Taotao Zhou",
note = "Funding Information: Funding The study was supported by the Helmut and Hannelore Greve Foundation , the YAEL Foundation , the German Research Foundation ( KFO306 , SCHR 781/3-2 ), and the National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) Oxford. Funding Information: Conflicts of interest These authors disclose the following: Ehud Zigmond received consultant fees from BiomX and lecture fees from Intercept, MSD, and Neopharm; and was or is involved in clinical trials for Cymabay, Gilead, Intercept, Chemomab, Mirum, and Genkyotex. Joost Drenth declares that The Radboudumc, on behalf of Joost Drenth, received honoraria or research grants from Gilead and Abbvie. Frank Hoentjen has served on advisory boards or as speaker for Abbvie, Janssen-Cilag, MSD, Takeda, Celltrion, TEVA, Sandoz, and Dr Falk; received funding (grants/honoraria) from Takeda, Janssen-Cilag, and Abbvie; and received consulting fees from Celgene. Christoph Schramm received a research grant from Galapagos, not related to this work. The remaining authors disclose no conflicts.",
year = "2023",
month = dec,
day = "1",
doi = "10.1016/j.cgh.2023.01.014",
language = "English",
volume = "21",
pages = "3448--3450.e3",
journal = "Clinical gastroenterology and hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "13",
}